Vitamin B2 & Cancer: Blocking Ferroptosis for New Therapies

Vitamin B2 Metabolism Linked to Cancer Cell Survival, Offering New Therapeutic Avenue

A common vitamin, riboflavin (vitamin B2), plays a surprising role in cancer cell survival, according to research published on March 13, 2026, by scientists at the Rudolf Virchow Centre at the University of Würzburg. The study reveals that vitamin B2 supports a protein, FSP1, crucial for preventing a specific type of cell death called ferroptosis, potentially opening new avenues for targeted cancer therapies.

Ferroptosis, a regulated form of cell death driven by excessive lipid peroxidation, has recently emerged as a promising target in cancer research. Unlike apoptosis, which relies on a cascade of enzymes, ferroptosis is triggered by iron-driven oxidative damage to cell membranes. Cancer cells, often growing in metabolically stressed environments, frequently develop mechanisms to evade ferroptosis, making it a key area of investigation for new treatment strategies.

The research team, led by José Pedro Friedmann Angeli, discovered that vitamin B2 isn’t simply a nutrient supporting general cellular function in tumor cells; it’s actively involved in protecting them from this specific form of programmed cell death. The vitamin is converted into molecules – FMN and FAD – that act as cofactors for enzymes involved in redox reactions, helping to maintain cellular stability. Crucially, FAD binds to and stabilizes FSP1, a protein that acts as a shield against ferroptosis.

“Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis,” explained PhD student Vera Skafar. The study, published in Nature Cell Biology, details how disrupting vitamin B2 metabolism weakens this protective mechanism. Researchers found that inhibiting the enzymes responsible for converting riboflavin into FAD – riboflavin kinase (RFK) and flavin adenine dinucleotide synthase (FLAD1) – led to a decrease in FSP1 levels and increased susceptibility to ferroptosis.

FSP1 Stability: The Key Connection

The team utilized genome editing techniques to disable RFK and FLAD1 in cancer cell lines, observing a significant reduction in FSP1. This reduction correlated with increased sensitivity to drugs that induce ferroptosis, such as RSL3 and ML210. Further analysis revealed that FAD binding is not only essential for FSP1’s activity but also for its structural stability. Without sufficient FAD, FSP1 becomes unstable and is degraded by the cell’s protein disposal system.

Interestingly, the researchers also tested roseoflavin, a bacterial analog of riboflavin and found that it could trigger ferroptosis even at very low concentrations when riboflavin levels were limited. This suggests that selectively targeting the vitamin B2 metabolic pathway could be a viable strategy for disrupting cancer cell defenses.

Implications for Cancer Therapy and Future Research

While these findings are promising, researchers caution that a direct therapeutic application isn’t imminent. Vitamin B2 is essential for the function of healthy cells, and a broad depletion of the vitamin would be unsafe. The focus now shifts to identifying ways to selectively disrupt the portion of the vitamin B2 metabolic pathway that supports FSP1 stabilization specifically within tumor cells.

The study highlights a novel connection between vitamin B2 metabolism and ferroptosis resistance, providing a rich resource for future research. The team at the University of Würzburg plans to develop inhibitors of vitamin B2 metabolism and evaluate their effectiveness in preclinical cancer models. This research represents a shift in understanding how cancer cells utilize essential nutrients not just for growth, but also for actively suppressing their own self-destruction mechanisms. The next steps will involve determining which cancer types are most reliant on this FSP1-dependent ferroptosis resistance and developing targeted therapies that exploit this vulnerability.